Northwestern Mutual Wealth Management
BCRX icon

Northwestern Mutual Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
10,254
+2,942
+40% +$26.6K ﹤0.01% 2266
2026
Q1 		$69.6K Buy
7,312
+1,185
+19% +$9.2K ﹤0.01% 2321
2025
Q4 		$47.8K Sell
6,127
-1
-0% -$7 ﹤0.01% 2414
2025
Q3 		$46.5K Buy
6,128
+1
+0% +$8 ﹤0.01% 2354
2025
Q2 		$54.9K Hold
6,127
– – ﹤0.01% 2221
2025
Q1 		$46K Sell
6,127
-2,740
-31% -$22.1K ﹤0.01% 2205
2024
Q4 		$66.7K Buy
8,867
+8,340
+1,583% +$63.3K ﹤0.01% 2068
2024
Q3 		$4K Buy
+527
New +$4.01K ﹤0.01% 2961
2022
Q3 		– Sell
-1,453
Closed -$15K – 3118
2022
Q2 		$15K Buy
+1,453
New +$15K ﹤0.01% 2365
2021
Q2 		– Sell
-1,267
Closed -$13K – 2999
2021
Q1 		$13K Buy
+1,267
New +$13.1K ﹤0.01% 2204

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Northwestern Mutual Wealth Management's BCRX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management increased its BioCryst Pharmaceuticals (BCRX) stake by 40% in Q2 2026, buying an estimated $26.6K and bringing the position to 10,254 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

Northwestern Mutual Wealth Management first reported a position in BCRX in Q1 2021 and has held it in 10 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Northwestern Mutual Wealth Management held 10,254 shares of BioCryst Pharmaceuticals worth $103K as of Q2 2026.
  • Northwestern Mutual Wealth Management bought 2,942 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $26.6K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #2266 holding.
  • Northwestern Mutual Wealth Management first reported a position in BioCryst Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.